Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HIV-VAC, Inc. (HIVC) Leading the world to a cure -- Ignore unavailable to you. Want to Upgrade?

To: hoffy who wrote (17)	6/10/2000 1:26:00 PM
From: Buckey	Respond to of 76

sounds good - I will sit on the buy as it appears to be breaking out - I suspect that this board may get a few hits niow - RB seems a bit more active - Maybe Yahoo - I dont go there

To: hoffy who wrote (17)	6/10/2000 8:56:00 PM
From: Buckey	Read Replies (1) \| Respond to of 76

WELL after doing hours of research - I discovered that HIVC is being covered by some OTC BB groups. here is the link to one as posted on RB ragingbull.com I will also cut and paste a part of it OK, HIVC might have something that could be proven to be a major medical breakthrough in history. Now question is that how much the stock should be valued in the market place. As far as we know, only one public company is doing something pretty like what HIVC does. It's VAXGEN, INC. (Nasdaq: VXGN). VXGN is developing preventive vaccines for worldwide use against HIV. Last year, VXGN has no sales with a loss over $24 million, but its stock commands a market cap at $252 million. OTCBB stocks are often valued at half of its peers on the NASADQ. Thus, this alone could give HIVC a fair market valuation at $4 per share, not to mention HIVC's vaccines which might be proven to be more effective than VXGN's. Wow! Don't forget its potential EPS at $1.20 per share as projected by the company in 2002. Shall we make another target price for the stock on the basis of this analysis? No, we are not going to give! We stick with our target price at $4 to $5! We are conservative, this is how our subscribers could benefit from our style in this risky OTCBB market filling with hype, bash, naked manipulation and short, not to mention all kinds of emotion! - Last March, the stock has been traded as high as $3.25 per share. Since then, the stock has been substantially declining to the current level. The stock has been traded extremely active in the past tens days. A rumor is circulating now about a possible buyout by a major pharmaceutical company. Also, we are hearing some major developments are in the works and should be announced shortly. If one of them or both are are true, the stock could be well over $5 before investors could grab any shares.